Shares of Biogen Inc. (BIIB) are having a good Monday. The biotech giant got a nice one-two punch of positive news: a fresh FDA approval for one of its key drugs and some encouraging early data for another pipeline candidate. It's the kind of day that reminds you why investors put up with the volatility of the biotech sector.

First up, the FDA gave the green light to a new, high-dose regimen for Spinraza (nusinersen), Biogen's treatment for spinal muscular atrophy (SMA). This isn't a new drug, but a new way to dose an existing one. The regimen involves two 50 mg doses given two weeks apart, followed by maintenance doses every four months. The idea is to give patients and doctors another option, potentially a more potent one.

The approval is backed by data from the Phase 2/3 DEVOTE study. In treatment-naïve infants, the high dose showed statistically significant improvements in motor function compared to an untreated control group. It's a solid win for maintaining Spinraza's position in the competitive SMA market. And it's not just a U.S. story—the high-dose regimen has also been approved in the European Union, Switzerland, and Japan. Biogen says it's working with regulators worldwide to roll this out, which suggests they see a meaningful global opportunity here.

But wait, there's more. Over the weekend, Biogen dropped some data on another drug in its pipeline: litifilimab. This one is being studied for cutaneous lupus erythematosus (CLE), an autoimmune skin disease that causes rashes and inflammation. The Phase 2 (Part A) results from the AMETHYST study were positive, with litifilimab meeting its primary endpoint.

At week 16, patients on the drug showed a 14.7% improvement in skin disease activity, compared to just 2.9% for those on a placebo. That's an 11.8 percentage point difference, which is statistically significant. The benefits appeared early (by week 4) and were sustained. By week 24, more patients on litifilimab hit key response milestones, and notably, 16.3% achieved minimal or no disease activity, while none on the placebo did. The Phase 3 portion of the study is still blinded, so the full picture isn't in yet, but this is promising news for a condition that hasn't seen a new targeted therapy in decades.

So, how is the stock reacting to all this? Well, it's up. At the time of publication, shares were trading around $186.62, up about 1.5% on the day. Looking at the technicals, the stock is trading just above its 20-day and 50-day simple moving averages, which suggests some short-term strength. Over the past 12 months, it's up an impressive 36.55%, trading closer to its 52-week highs than lows.

That said, momentum indicators are sending mixed signals. The Relative Strength Index (RSI) is neutral, suggesting the stock isn't overbought right now. But the Moving Average Convergence Divergence (MACD) is bullish, hinting at potential for more upward movement. Traders might be watching key resistance around $193 and support near $181.

All in all, it's a good news day for Biogen. An FDA approval expands the commercial life of an important product, and promising pipeline data offers a glimpse of potential future growth. For investors, it's a reminder that in biotech, progress often comes in doses—sometimes even high ones.